Applied Genetic Technologies (AGTC) Stock Forecast, Price & News

Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions

Is Applied Genetic Technologies a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Applied Genetic Technologies stock.
View analyst ratings for Applied Genetic Technologies or view top-rated stocks.

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) announced its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same period in the prior year, the company earned ($0.60) earnings per share.
View Applied Genetic Technologies' earnings history.

What price target have analysts set for AGTC?

6 Wall Street analysts have issued 1-year target prices for Applied Genetic Technologies' shares. Their forecasts range from $10.00 to $24.00. On average, they anticipate Applied Genetic Technologies' share price to reach $15.00 in the next year. This suggests a possible upside of 1,905.6% from the stock's current price.
View analysts' price targets for Applied Genetic Technologies or view top-rated stocks among Wall Street analysts.

Who are Applied Genetic Technologies' key executives?

Applied Genetic Technologies' management team includes the following people:

• Ms. Susan B. Washer, Pres, CEO & Director (Age 61, Pay $788.55k) (LinkedIn Profile)
• Mr. Stephen W. Potter, VP & Chief Bus. Officer (Age 66, Pay $492.17k)
• Dr. Nicholas Muzyczka, Co-Founder
• Dr. Barry J. Byrne M.D., Ph.D., Co-Founder
• Dr. William W. Hauswirth, Co-Founder & Member of Ophthalmology Scientific Advisory Board
• Dr. Richard Jude Samulski Ph.D., Co-Founder
• Dr. Terence R. Flotte M.D., Co-Founder
• Mr. Jonathan I. Lieber M.B.A., Chief Financial Officer (Age 52)
• Mr. Gerald Anthony Reynolds, Chief Accounting Officer, Principal Accounting Officer & Treasurer
• Dr. Abraham Scaria Ph.D., Chief Scientific Officer

Who are some of Applied Genetic Technologies' key competitors?

Some companies that are related to Applied Genetic Technologies include Big Cypress Acquisition (BCYP), CEL-SCI (CVM), Candel Therapeutics (CADL), Jasper Therapeutics (JSPR), Genenta Science (GNTA), Rubius Therapeutics (RUBY), Finch Therapeutics Group (FNCH), La Jolla Pharmaceutical (LJPC), Surface Oncology (SURF), Cortexyme (CRTX), Passage Bio (PASG), Brainstorm Cell Therapeutics (BCLI), Precision BioSciences (DTIL), Aptose Biosciences (APTO) and TCR2 Therapeutics (TCRR).
View all of AGTC's competitors.

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Who are Applied Genetic Technologies' major shareholders?

Applied Genetic Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.62%), Assenagon Asset Management S.A. (0.65%), Group One Trading L.P. (0.00%), Dimensional Fund Advisors LP (0.47%), CI Investments Inc. (0.38%) and State Street Corp (0.30%).
View institutional ownership trends for Applied Genetic Technologies.

Which institutional investors are selling Applied Genetic Technologies stock?

AGTC stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Dimensional Fund Advisors LP, State Street Corp, and Simplex Trading LLC.
View insider buying and selling activity for Applied Genetic Technologies or view top insider-selling stocks.

Which institutional investors are buying Applied Genetic Technologies stock?

AGTC stock was acquired by a variety of institutional investors in the last quarter, including Group One Trading L.P., Vanguard Group Inc., CI Investments Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Applied Genetic Technologies or or view top insider-buying stocks.

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $0.75.

How much money does Applied Genetic Technologies make?

Applied Genetic Technologies has a market capitalization of $32.10 million and generates $500 thousand in revenue each year. The biotechnology company earns $-57.83 million in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Applied Genetic Technologies have?

Applied Genetic Technologies employs 83 workers across the globe.

What is Applied Genetic Technologies' official website?

The official website for Applied Genetic Technologies is www.agtc.com.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at (386) 462-2204 or via email at [email protected].